Molecular Partners Ag (MOLN) Net Margin (2020 - 2026)
Molecular Partners Ag (MOLN) posted quarterly Net Margin of 97.82% for Q1 2026, up 610.0% year-on-year from 13.78% in Q1 2025, and down 100.07% on a QoQ basis from 143942.29% in Q4 2025.
Molecular Partners Ag (MOLN) Net Margin (2020 - 2026) Analysis & Trends
Molecular Partners Ag (MOLN) has reported Net Margin for 7 consecutive years, with 97.82% the latest figure, recorded in Q1 2026.
- Quarterly Net Margin rose 610.0% year-over-year to 97.82% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 2203566.36% (up 220356526.0% YoY) and the FY2025 annual result came in at 138209982.79%, up 13820715079.0% from the prior year.
- Net Margin declined to 97.82% in Q1 2026 per MOLN's latest filing, from 143942.29% in the prior quarter.
- Over the last five years, Net Margin for MOLN reached as high as 143942.29% in Q4 2025 and fell as low as 972404.9% in Q2 2024.
- A 5-year average of 49198.15% and a median of 97.82% in 2026 frame the typical range for Net Margin.
- Annual changes were most pronounced in 2024 — Net Margin sank 96855261 bps — and 2025, when it jumped 97228708 bps.
- Year by year, Net Margin stood at 82.13% in 2022, then sank by 1207 bps to 909.17% in 2023, then surged by 100 bps to 1.1% in 2024, then surged by 13113852 bps to 143942.29% in 2025, then plunged by 100 bps to 97.82% in 2026.
- According to Business Quant data, Net Margin over the past three periods registered 97.82%, 143942.29%, and 98.31% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 15.02% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 34.53% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 20.17% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 30.33% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Molecular Partners Ag | 147.97 Mn | 147.97 Mn | - | -97.82% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -97.82% |
| Dec 31, 2025 | 143,942.29% |
| Sep 30, 2025 | -98.31% |
| Jun 30, 2025 | -117.82% |
| Mar 31, 2025 | -103.92% |
| Dec 31, 2024 | 1.10% |
| Sep 30, 2024 | -2,409.65% |
| Jun 30, 2024 | -972,404.90% |
| Mar 31, 2024 | 0.00% |
| Dec 31, 2023 | -909.17% |
| Sep 30, 2023 | -450.40% |
| Jun 30, 2023 | -3,852.29% |
| Mar 31, 2023 | 0.00% |
| Dec 31, 2022 | 82.13% |
| Sep 30, 2022 | 0.00% |
| Jun 30, 2022 | -38.46% |
| Mar 31, 2022 | 88.62% |
| Dec 31, 2021 | -654.00% |
| Sep 30, 2021 | -348.55% |
| Jun 30, 2021 | 3.43% |